Teneobio and its next-gen cancer work acquired by Amgen
Amgen has penned a major new buyout deal to boost its oncology pipeline further. The biopharma is putting USD 900 million down upfront, with USD 1.6 billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets.
The deal adds TNB-585, a phase 1 bispecific T cell-engager zeroed in at metastatic castrate-resistant prostate cancer (mCRPC), and several preclinical oncology pipeline assets with the potential for near-term IND filings.
TNB-585 complements Amgen's existing prostate cancer portfolio, in...
